Corteva, Inc. current report, 21 January 2021

Full document

Corteva, Inc. Form 8-K Summary

Report date: January 21, 2021; the filing was signed January 22, 2021. The filing concerns legal settlements and a binding memorandum of understanding rather than operating results for a reported quarter or year.

Business Context and Reporting Period

Corteva is involved in legacy liabilities arising from historical PFOA and other PFAS activities associated with E. I. du Pont de Nemours and Company, which became a Corteva subsidiary following the DowDuPont separation. The filing addresses the Chemours Separation Agreement, related litigation and arbitration, and personal-injury claims in Ohio and West Virginia.

Financial Metrics and Obligations

  • Revenue, profit, cash flow, margins and debt: The filing does not provide operating or balance-sheet metrics for the period.
  • PFOA litigation settlement: Approximately $83 million will resolve the applicable multidistrict litigation claims. EID and DuPont will each contribute approximately $27 million, and Chemours will contribute approximately $29 million. Corteva will record its share as a charge to income from discontinued operations.
  • PFAS cost-sharing arrangement: Qualified future PFAS spending will be shared 50% by Chemours and 50% collectively by DuPont and Corteva. DuPont’s and Corteva’s combined share is capped at $2 billion.
  • Escrow funding: For 2021 and 2022, Chemours will deposit $100 million annually and DuPont and Corteva will collectively deposit $100 million annually. From 2023 through 2028, each side will generally deposit $50 million annually. If the escrow balance is below $700 million at December 31, 2028, additional funding may be required beginning September 30, 2029.
  • Internal Corteva-DuPont allocation: Under the June 1, 2019 Letter Agreement, costs are shared 50%/50% up to $300 million, after which Corteva and DuPont share costs 29% and 71%, respectively.
  • Charges related to the MOU will be recognized over the arrangement’s term as discontinued-operations expense when the liabilities become probable and estimable.

Material Changes Versus the Prior Comparable Period

  • The parties entered into a binding MOU intended to settle and release claims relating to the Delaware Litigation and Pending Arbitration.
  • The Pending Arbitration is to be jointly terminated, and Chemours agreed to release specified claims concerning the Chemours separation and allocation of liabilities, subject to exceptions.
  • Approximately 96 personal-injury cases filed after the 2017 settlement were addressed through a settlement of the multidistrict litigation, except for the Abbott matter and other stated exclusions.
  • The MOU establishes a long-term PFAS liability-sharing and escrow framework extending potentially through 2040, or until aggregate Qualified Spend reaches $4 billion.

Guidance, Outlook, Risks and Unusual Items

  • No operating or earnings guidance is provided.
  • The MOU remains subject to the parties entering into additional definitive agreements reflecting its terms, contemplated by February 28, 2021.
  • Key risks include failure of the definitive agreements to become effective, future PFAS or PFOA litigation, performance by DuPont and Chemours of their obligations, the final terms of the definitive agreements, and the ultimate amount and timing of liabilities.
  • The settlement is expressly a compromise and is not an admission of liability or fault by Corteva, DuPont, EID or Chemours.
  • The Abbott case was not included in the settlement and remained pending motions for a new trial.
  • Charges are expected to affect discontinued operations rather than continuing operating results, subject to probability and estimability requirements.

Important Facts for Investors to Verify

  1. Whether the definitive agreements contemplated by the MOU were executed and became effective.
  2. The precise amount ultimately recorded by Corteva for the approximately $83 million PFOA settlement.
  3. The accounting treatment and timing of future PFAS liabilities, escrow contributions and any replenishment payments.
  4. The status and outcome of the Abbott matter and any excluded or future personal-injury claims.
  5. Whether actual Qualified Spend approaches the $4 billion aggregate threshold or Corteva and DuPont’s combined $2 billion exposure cap.
  6. The detailed exceptions, indemnification provisions and allocation mechanics in the full MOU and related Letter Agreement.